Oil prices rise from over 1-mth low with Russia crude buyer sanctions in focus
BioSig Technologies (NASDAQ:BSGM), Inc., a medical technology company with a market capitalization of $44 million, has successfully regained compliance with Nasdaq’s minimum bid price requirement. The company received notification from Nasdaq Listing Qualifications staff on April 11, 2025, indicating that its common stock had not maintained the minimum bid price of $1.00 over the prior 30 consecutive business days as required by Nasdaq’s Listing Rules.
BioSig’s common stock has since achieved a closing bid price of at least $1.00 per share for 10 consecutive business days, from April 30, 2025, to May 13, 2025. The stock has shown remarkable momentum, surging 52% in the past week to $2.56. With this achievement, BioSig has met the compliance with Listing Rule 5550(a)(2), and the matter is now considered closed. InvestingPro analysis indicates the stock is currently in overbought territory, with additional technical insights available to subscribers.
The notice of non-compliance is a standard communication when a company’s stock trades below the required threshold. The return to compliance indicates that BioSig’s stock price has recovered sufficiently to meet Nasdaq’s requirements, which is a positive development for the company.
This news is based on a recent SEC filing by BioSig Technologies, Inc. The company, incorporated in Delaware with headquarters in Los Angeles, California, specializes in electromedical and electrotherapeutic apparatus. It is listed under the trading symbol BSGM on the NASDAQ Capital Market.
In other recent news, BioSig Technologies has announced a strategic merger with Streamex Exchange Corporation in an all-stock transaction. This merger aims to integrate Streamex’s commodity-focused tokenization platform with BioSig’s operations, with Streamex’s stockholders expected to own a significant portion of BioSig post-merger. Additionally, BioSig has changed its accounting firm, appointing CBIZ (NYSE:CBZ) CPAs P.C. following the resignation of Marcum LLP, with no disagreements reported on accounting principles or practices. Meanwhile, BioSig has been notified by Nasdaq regarding non-compliance with the minimum bid price requirement, giving the company until October 2025 to regain compliance. On a positive note, BioSig’s recent capital-raising efforts may have met Nasdaq’s stockholders’ equity requirement, potentially ensuring continued listing. The company is waiting for formal confirmation from Nasdaq regarding compliance with the equity rule. These developments reflect BioSig’s ongoing efforts to align with Nasdaq’s standards and expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.